Bristol Myers Squibb (NYSE:BMY) will price its latest schizophrenia medication at $22,500 per year in the United Kingdom, the same as in the United States, according to the Financial Times.
The company has opted to standardize the cost of the therapy across both markets, offering patients in the UK and US equal pricing for this new schizophrenia treatment. This launch marks one of Bristol Myers Squibb’s recent expansions into the mental health pharmaceutical sector, with a focus on managing schizophrenia.
Bristol Myers Squibb stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.